Open Access

Mutation spectrum of Egyptian children with cystic fibrosis

  • Walaa Aboulkasem Shahin1Email author,
  • Dina Ahmed Mehaney2 and
  • Mona Mostafa El-Falaki1
SpringerPlus20165:686

https://doi.org/10.1186/s40064-016-2338-7

Received: 29 April 2016

Accepted: 11 May 2016

Published: 20 May 2016

Abstract

Objective

To know the common CFTR mutations in the Egyptian patients with cystic fibrosis as it was previously thought to be uncommon disease in Egypt.

Methods

This is a cross sectional study of 60 patients diagnosed as cystic fibrosis by sweat chloride testing. They were enrolled from the Allergy and Pulmonology Unit Children’s Hospital Cairo University. They were screened for the presence of the frequent 36 mutations in Caucasians by reverse hybridization line probe technique, using INNO-LiPACFTR19 and CFTR17 + Tn kits.

Results

Most of patients presented with classic manifestations of CF such as variable pulmonary disease and pancreatic insufficiency, and hepatomegaly with or without ascites. The mutations detected were F508 del (58 %), 2183AA/G (10 %), N1303K (6 %), I148T (4 %), W1282X (4 %), G155D (2 %), CFTRdel2-3 (21 KB) (2 %), 3199del6 (2 %), R347P (2 %). Unique to the Egyptian population are these mutations R1162X and A544E (6, 4 %) respectively they were found in our cohort study and were not reported elsewhere in the Arab population till now. There was no association between the initial clinical presentation of CF and the genotypes detected.

Conclusion

The F508 del is still the most commonly encountered mutation (58 %), however other rare mutations were identified where each ranged from (2 to 10 %).

Keywords

CFTR mutationsCystic fibrosisEgyptF508del

Background

Cystic fibrosis (CF), the most common lethal genetic disease in whites, affects approximately 70,000 people worldwide (Bethesda 2009). The basic defect in CF cells is the faulty chloride transport, which causes dehydration of secretions with hyper viscous mucus and leads to chronic airway obstruction, exocrine pancreatic insufficiency and intestinal malabsorption. While many organs are affected in CF, pulmonary disease is the major cause of morbidity and mortality (Lubamba et al. 2012).

Persistent respiratory symptoms, bronchiectasis, or clubbing should prompt a diagnostic evaluation for CF. Although nasal polyps can be seen in other conditions; their presence should suggest the possibility of CF (Voter and Clement 2008). The accurate knowledge of CFTR (cystic fibrosis Transmembrane conductance regulator) mutations is of obvious interest in clinical testing, as it improves CF prevention programs of neonatal screening, heterozygote screening in partners of CF patients or partners of carriers. Reporting updated data specifically for each group of populations is also crucial for deeper understanding of CF genetics (Des Georges et al. 2004).

CFTR mutations vary in their frequency and distribution in different populations. CF was previously thought to be rare among Arabs, however there are some published data denoting its existence (Banjar 1999; Farra et al. 2010; Siryani et al. 2015).

Our aim in the present study was to detect the common mutations encountered in a group of Egyptian CF population, using the commercially available kits. Better understanding of the genetic background of our population and its relation to the clinical presentation of CF, will allow us for providing optimum care for our patients.

Subjects and methods

Subjects

This pilot study included 60 CF patients enrolled from to the CF clinic of the Allergy and Pulmonology Unit, Children’s Hospital Cairo University over a period of 2 years (January 2013–January 2015); where these patients came regularly for follow up and receiving medications. Patients were diagnosed as having CF based on clinical presentations and confirmed by sweat chloride testing, which was repeated twice as per the cystic fibrosis foundation (CFF) guidelines (Le Grys et al. 2007). Blood samples were withdrawn for genetic testing of the frequent 36 mutations in Caucasians (Lenarduzzi et al. 2014).

Quantitative sweat chloride testing

Sweat stimulation was done using the pilocarpine iontophoresis for induction and sweat collection by the Wescor macroduct sweat collection system (NCCLS 2000). The sweat sample was analyzed quantitatively by the thiocyanate colorimetric method (Skeggs and Hochstrasser 1964). Test result higher than 60 mmol/L was considered positive and consistent with the diagnosis of CF.

Molecular analysis

DNA was extracted from whole blood samples using QIAamp Mini Kit (QIAGEN, USA). All patients with positive sweat chloride test were screened for the presence of the 36 frequent mutations in Caucasians, using INNO-LiPACFTR19 and CFTR17 + Tn kits (Innogenetics, Ghent, Belgium). This is a multi parameter line probe assay based on the reverse hybridization principle for the simultaneous detection and identification of 36 CF-related mutations and their wild-type sequences in human whole blood.

Briefly, multiplex PCR was done in a reagent mix containing biotinylated primers, dNTPs and hot start Taq polymerase. Amplification was done according to the manufacturer’s protocol: 30 cycles of denaturation at 95 °C for 1 min, annealing at 57 °C for 1 min, extension at 68 °C for 1 min, then final extension at 68 °C for 10 min. Amplified biotinylated DNA was chemically denatured and hybridized with specific oligonucleotide probes immobilized on membrane-based strips. Streptavidin conjugated with alkaline phosphatase was added to bind to any biotinylated hybrid formed. Incubation with a substrate solution containing a specific chromogen resulted in a pink color and positive patterns were recorded.

Statistical methods

Data was analyzed using IBM SPSS (software package used for statistical analysis) Advanced Statistics version 20.0 (SPSS Inc., Chicago, IL). Numerical data were expressed as mean and standard deviation (SD) or median and range as appropriate. Qualitative data were expressed as frequency and percentage.

Results

The present study enrolled 60 Egyptian children with CF, their age ranged from 6 months to 14 years. Thirty eight of them were males and 22 were females. Positive consanguinity was reported in 57 % of patients. 23 % of patients had positive family history of CF; the most frequent clinical presentations were pulmonary disease 84 % followed by pancreatic insufficiency (56 %). Demographic and clinical data of the studied population are summarized in Table 1.
Table 1

Demographic data and clinical presentations of the study population

Variables

N = 60 (%)

Age (years)a

5 (0.5–14)

Gender

Male

38 (63)

Female

22 (37)

Positive family history of CF

14 (23)

Positive consanguinity

34 (57)

Clinical presentations

Pulmonary disease

56 (93)

Pancreatic insufficiency

52 (87)

Hepatic disease

9 (15)

Intestinal obstruction

2 (3)

Nasal polyps

13 (22)

Sinusitis

13 (22)

Pseudo barter

1 (1.66)

Data are presented as number (percent)

aData are presented as median (range)

Twenty seven out of the 60 patients proved to be positive for the 36 mutations searched for. Among the 120 alleles examined, 50 positive alleles (41.6 %) were detected as shown in Table 2.
Table 2

Frequency of mutations detected among the studied patients

Mutation

Allele frequency, N = 50 (%)

Class of mutation

ΔF508

29 (58)

Class II

Non-functional, degraded mutant CFTR protein

2183AA/G

5 (10)

Class I

Shortened protein

N1303K

3 (6)

Class II

R1162X

3 (6)

Class IV

Reduced chloride conductance

I148T

2 (4)

Alone it is a neutral polymorphism not causing CF

W1282X

2 (4)

Class I

Shortened protein

A544E

2 (4)

 

G155D

1 (2)

Class III

Channel cannot be regulated properly

CFTRdel2,3 (21 KB)

1 (2)

Class I

Shortened protein

3199del6

1 (2)

Class II

R347P

1 (2)

Class IV

Reduced chloride conductance

Data are presented as number (percent)

The most commonly encountered mutations were F508del (58 %) followed by 2183AA/G (10 %). Testing of intron 8 (T) n variants revealed that the most frequent allele was the T7 allele (71.7 %) followed by the T9 allele (25.8 %) and the T5 allele (2.5 %). The mean ± (SD) age of patients with positive mutational testing was 6.7 (4.3) years. Male:Female ratio was 2.6:1. Most of patients (24/25) presented with pulmonary disease and pancreatic insufficiency. The mean (SD) sweat chloride concentration was 87.5 (12.5) mmol/L; ranging from 69 to 110 mmol/L. Positive consanguinity was present in 57 % of patients. Positive family history was present in 23 % of cases. Results of sweat chloride concentrations; genotypes and phenotypes of the 25 positive patients with are given in Table 3.
Table 3

Demographic, phenotype and genotype characteristics of the 27 patients with positive mutations

Pt No

Sex

Age (Y)

Genotype

T repeats

Sweat chloride

Phenotype

1

M

2

Hetero, R347P

T7

79

PS/Pul. Dis.

2

F

3

Homo, 2183AA/G

T7

69

PI/Pul. Dis.

3

F

4

I148T/3199del6

T7/T9

104

PI/Pul. Dis., Rectal prolapse

4

M

6

Hetero, N1303K

T7

71

PI/Pul. Dis.

5

M

7

Homo, DeltaF508

T7

95

PI/Pul. Dis.

6

M

3

Homo, N1303K

T7

70

PI/Pul. Dis.

7

M

11

Homo, DeltaF508

T7

104

PI/Pul. Dis./Nasal polyps/sinusitis

8

M

4

Homo, DeltaF508

T7

88

PI/Pul. Dis./Hepat. Dis.

9

F

14

DeltaF508/W1282X

T7

90

PI/Pul. Dis.

10

M

5

2183AA/G/R1162X

T7

99

PI/Pul. Dis./Nasal polyps

11

M

17

DeltaF508/W1282X

T7

100

PI/Pul. Dis.

12

F

3

Homo, DeltaF508

T7

76

PI/Pul. Dis.

13

M

5

Homo, DeltaF508

T7

105

PI/Pul. Dis.

14

F

8

Homo DeltaF508

T7

102

PI/Pul. Dis./Nasal polyps/sinusitis

15

M

7

Homo, DeltaF508

T7

85

PI/Pul. Dis.

16

M

17

2183AA/G/R1162X

T7

75

Nasal polyps/sinusitis

17

F

5

Homo, DeltaF508

T7

70

PI/Pul. Dis./Hepat. Dis.

18

F

5

Hetero, CFTR del 2,3 (21 kb)

T7

75

PI/Pul. Dis.

19

M

8

Homo, DeltaF508

T7

82

PI/Pul. Dis./sinusitis

20

M

8

Homo, DeltaF508

T7

80

PI/Pul. Dis./Nasal polyps/sinusitis/Hepat. Dis.

21

F

6

I148T/AA2183/G

T7

95

PI/Pul. Dis.

22

M

8

Homo, DeltaF508

T7

100

PI/Pul. Dis./Nasal polyps/sinusitis/Hepat. Dis.

23

M

4

DeltaF508/R1162X

T9

90

PI/Pul. Dis./Hepat. Dis

24

M

3

Homo, A455E

T7

75

PI/Pul. Dis.

25

F

1

Hetero, G551D

T7

110

PI/Pul. Dis./Pseudo Barter syndrome

26

M

5

Homo, DeltaF508

T7

80

PI/Pul. Dis./Nasal polyps/sinusitis

27

M

14

Homo, DeltaF508

T7

95

PI/Pul. Dis./Nasal polyps/sinusitis

Y yes, N no, Pt patient, Y years, M male, F female, FH family history, Pul. Dis. pulmonary disease such as chronic cough, wheezing or recurrent bronchitis, PI pancreatic insufficiency, PS pancreatic sufficiency, Hepat. Dis. hepatic disease such as hepatomegaly, ascites. T7, T5 and T9 refer to the allele variants commonly known as IVS8 Tn repeats. Homo homozygote, Hetero heterozygote

Discussion

Although the most common CFTR mutation is F508del, which accounts for 65–85 % of all reported CFTR mutations in Caucasian populations, New and novel mutations have been detected in the Egyptian CF population as well as the different Arab communities who carry CFTR mutations that had never been described in the Caucasians (Farra et al. 2010). Limited data are available about CF in Egypt. Only two recently published articles highlighted the presence of many cases assuming that it is not uncommon in Egypt (Naguib et al. 2007; El-Falaki et al. 2014).

Our study addressed the most common CFTR mutations in another 60 CF patients different from those included in our previous study (El-Falaki et al. 2014). Most of patients included in the sample had typical clinical manifestations of repeated chest infection, variable pulmonary disease, steatorrhea, failure to thrive and early liver disease. The mutations detected were F508 del (58 %), 2183AA/G (10 %), N1303K (6 %), I148T (4 %), W1282X (4 %), G155D (2 %), CFTRdel2-3 (21 KB) (2 %), 3199del6 (2 %), R347P (2 %). The F508 del represented (58 %) of the mutations detected in our study population, this was in near frequency to what was found in United Arab Emirates and Tunisia where F508del represents 94 and 50.74 % respectively (Frossard et al. 1998; Messaoud et al. 2005). Where as in other populations like Iran F508del was found in only 18 % (Alibakhshi et al. 2008).

Our patients who were homozygous for theF508del had severe pulmonary disease, severe PI and liver disease. These finding were in accordance with Castellani et al. (2008) who showed that Patients homozygous for F508del usually have more pronounced clinical manifestations compared to compound heterozygotes and genotypes without F508del, although these differences are highly variable. Patients homozygous for the F508del mutation have an earlier diagnosis of disease, higher sweat chloride levels, younger age at presentation and are more likely to be pancreatic insufficient (Castellani et al. 2008).

The initial presentation of one female patient was pseudo Bartter’s syndrome (PBS) at the age of 6 month who later developed chest infection and steatorrhea. She was heterozygous for G551D mutation, which is the third most common CF-causing mutation, and is present in about 4 % of patients (Kotha and Clancy 2013), it was found in United Kingdom and central Europe, Syria and Egypt. We report here for the first time in the literature this mutation in a case of PBS. Another previously reported mutation in one patient with CF and presenting with PBS, severe dehydration and hypochloremic metabolic acidosis in 2011 were (3849 + 1G>A and 4382delA compound heterozygosity) (Nahida et al. 2011), this was in addition to M2789 + 5G and F508del described in 2013 in Jordan (Dahabreh and Najada 2013) and D575G mutation in southern Italy (Salvatore et al. 2004).

The mutation 2183AA/G was encountered in 10 % of our studied alleles. It is a frameshift mutation (A to G at 2183 and deletion of A at 2184). It was encountered in similar frequency in Syria and Algeria (Jarjour et al. 2015; Loumi et al. 2008). It was also found in Southern Europe, Iran, and Latin America (Rolfini and Cabrini 1993). Patients who have this mutation had classic clinical manifestations of variable pulmonary disease and pancreatic insufficiency which agreed with other studies suggesting that this phenotype could lead to moderate–severe symptoms (Pereira et al. 1999). The mutations R1162X and A544E are present in the Egyptian population in a ratio of 6 and 4 %, respectively. To our knowledge they were not described elsewhere in the Arab population till now.

The mutation R1162X was detected in three patients; two were heterozygotes for 2183AA/G/R1162X, but with variable pulmonary and pancreatic involvement, recurrent nasal polyps and sinusitis. However when this mutation R1162X comes with F508 it leads to more severe symptoms in addition to liver affection. This is a very common nonsense mutation in north eastern Italy which usually presents with mild to moderate pulmonary disease and severe pancreatic insufficiency (Rolfini and Cabrini 1993).

The mutation A544E was detected in one patient as homozygous mutation, this patient had mild pulmonary disease and PI with failure to thrive. This exceedingly rare A455E mutation (identified in only eight patients in the United States) is the best described CF-causing mutation associated with a mild CF lung phenotype (Walker et al. 1997). Two Patients having the N1303K mutation either homozygous or heterozygous have the same classic clinical presentation of pulmonary affection and pancreatic insufficiency. This was in contrast to Van Hoorenbeeck et al. (2007) who found that this mutation was associated with mild atypical CF disease presenting at variable ages (Van Hoorenbeeck et al. 2007).

The mutation I148T was found in a compound heterozygotes form with 2183AA/G in one patient and with 3199del6 in another patient who had rectal prolapse in addition to the classic CF pulmonary disease and pancreatic insufficiency. This was in accordance to the study done in 2004 declaring that I148T exists as a complex allele with 3199del6 in patients with clinical CF and recommended that Reflex testing for 3199del6 should be considered whenever I148T is identified (Monaghan et al. 2004). The mutation W1282X detected in our study was also found in other Arab countries like Lebanon, Palestine, Syria, Tunisia and Algeria (Farra et al. 2010). However, it showed a higher frequency than F508del in some populations such as Ashkenazi Jews (Shoshani et al. 1992).

CF patients in our study bearing the W1282X mutation were in compound heterozygote form with F508del. They have severe pulmonary and pancreatic disease, this was in accordance with Rolfini and Cabrini in 1993 who found that CF patients bearing W1282X present severe pulmonary and pancreatic disease, whereas patients carrying other nonsense mutations such as G542X, R553X, S1255X, R1162X, and W1316X show a severe pancreatic but mild pulmonary illness (Rolfini and Cabrini 1993).

Our study showed that the mutation R347P was detected once (2 %) in a compound heterozygous form with unknown other mutations. It occurs with an overall worldwide frequency of about 0.2 %. This patient had mild pulmonary disease and pancreatic sufficiency, which differs from what Vron et al. found during studying a group of 19 CF patients with this mutation of German, Bulgarian, Czech, and Slovak origin; where most patients presented with early disease onset, pancreatic insufficiency and early pulmonary involvement, suggesting that this mutation can lead to a severe course of CF (Varon et al. 1995).

The deletion mutation CFTRdel2,3 (21 KB) was found in a compound heterozygous form with unknown other mutation in another patient with moderate to severe pulmonary disease and pancreatic insufficiency. These finding agreed with Dork et al. who found that this deletion represents a severe mutation associated with pancreatic insufficiency and early age at diagnosis, and that the 21-kb deletion is a frequent and severe CF mutation in populations of Eastern- and Western-Slavic descent (Dork et al. 2000).

Conclusion

This study addressed the CFTR mutations in Egyptian patients with cystic fibrosis. The F508 del is the most commonly encountered mutation, yet there are some mutations that haven’t been described before. Genotype-phenotype correlation is not always easy to establish; genetic explanations are still being sought for different clinical manifestations in individuals with identical mutations, although the explanation may lie in interplay of genetic, infectious, and environmental factors. DNA sequencing is required in order to detect further mutations that will provide the basis for neonatal screening program as well as prenatal diagnosis.

What is already known?

Cystic Fibrosis is less common in Egypt and may not be considered in the differential diagnosis by many physicians. Profile of CFTR mutations for Egyptians remains unknown.

What this study adds?

The commonest mutation detected in the Egyptians with CF was ∆ F508 del (58 %), followed by other mutations 2183AA/G (10 %), N1303K (6 %), I148T (4 %), W1282X (4 %), G155D (2 %), CFTRdel2-3 (21 KB) (2 %), 3199del6 (2 %), R347P (2 %).

Limitations of the study

  1. (a)

    Limited mutation screening panel of 36 mutations only was used. It is now known that there are more than 2000 CFTR mutations.

     
  2. (b)

    It represents single center data and may not reflect the prevalence of these mutations in the general Egyptian population.

     

Abbreviations

CF: 

cystic fibrosis

CFTR: 

cystic fibrosis transmembrane conductance regulator

CFF: 

cystic fibrosis foundation

Declarations

Authors’ contributions

All authors have contributed to the conception and design of the study, acquisition of data and final approval of the version to be submitted. DAM: contributed to Laboratory work and Statistical analysis of data. WAS: contributed for Collection of clinical data, drafting and writing the article. MMEF: contributed to its final revision. All authors read and approved the final manuscript.

Acknowledgements

We are extremely grateful to the participating patients and their parents. We also thank our skilled staff nurses who helped us in the filing and arrangements of patient’s visits.

Competing interests

The authors declare that they have no competing interests.

Ethics approval and consent to participate

The aim and nature of the study was explained for each parent before inclusion. An informed written consent was obtained from parents or caregivers before enrollment. The study design conformed to the requirements of latest revision of Helsinki Declaration of Bioethics (2008). The Scientific Research Committee of Pediatrics Department-Faculty of Medicine—Cairo University revised and approved the study design.

Source of funding

Cairo University research fund.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors’ Affiliations

(1)
Department of Allergy and Pulmonology, Children’s Hospital, Cairo University
(2)
Department of Clinical and Chemical Pathology, Cairo University

References

  1. Alibakhshi R, Kianishirazi R, Cassiman JJ, Zamani M, Cuppens H (2008) Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. J Cyst Fibros 7(2):102–109 (Epub 2007 July 27) View ArticleGoogle Scholar
  2. Banjar H (1999) Geographic distribution of cystic fibrosis transmembrane regulator gene mutations in Saudi Arabia. East Mediterr Health J 5:1230–1235Google Scholar
  3. Bethesda M (2009) Patient registry: annual data report 2008. Cystic Fibrosis Foundation. www.cff.org
  4. Castellani C, Cuppens H, Macek M Jr, Cassiman JJ, Kerem E, Durie P et al (2008) Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros 7:179–196. doi:10.1016/j.jcf.2008.03.009 View ArticleGoogle Scholar
  5. Dahabreh MM, Najada AS (2013) Pseudo-bartter syndrome, pattern and correlation with other cystic fibrosis features. Saudi J Kidney Dis Transpl 24:292–296View ArticleGoogle Scholar
  6. Des Georges M, Guittard C, Altieri JP, Templin C, Sarles J, Sarda P et al (2004) High heterogeneity of CFTR mutations and unexpected low incidence of cystic fibrosis in the Mediterranean France. J Cyst Fibros 3:265–272View ArticleGoogle Scholar
  7. Dork T, Macek M Jr, Mekus F, Tummler B, Tzountzouris J, Casals T et al (2000) Characterization of a novel 21-kb deletion, CFTRdele2,3 (21 kb), in the CFTR gene: a cystic fibrosis mutation of Slavic origin common in Central and East Europe. Hum Genet 106:259–268View ArticleGoogle Scholar
  8. El-Falaki MM, Shahin WA, El-Basha NR, Ali AA, Mehaney DA, El-Attar MM (2014) Profile of cystic fibrosis in a single referral center in Egypt. J Adv Res 5:563–568. doi:10.1016/j.jare.2013.07.005 View ArticleGoogle Scholar
  9. Farra C, Menassa R, Awwad J, Morel Y, Salameh P, Yazbeck K et al (2010) Mutational spectrum of cystic fibrosis in the Lebanese population. J Cyst Fibros 9:406–410. doi:10.1016/j.jcf.2010.08.001 View ArticleGoogle Scholar
  10. Frossard PM, Girodon E, Dawson KP, Ghanem N, Plassa F, Lestringant GG et al (1998) Identification of cystic fibrosis mutations in the United Arab Emirates. Hum Mutat 11:412–413View ArticleGoogle Scholar
  11. Jarjour RA, Al-Berrawi S, Ammar S, Majdalawi R (2015) Spectrum of cystic fibrosis mutations in Syrian patients. Minerva Pediatr (EPUB ahead of print) Google Scholar
  12. Kotha K, Clancy JP (2013) Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence. Ther Adv Respir Dis 7:288–296. doi:10.1177/1753465813502115 View ArticleGoogle Scholar
  13. Le Grys VA, Yankaskas JR, Quittell LM, Marshall BC, Mogayzel PJ Jr (2007) Diagnostic sweat testing: the cystic fibrosis foundation guidelines. J Pediatr 151(1):85–89. doi:10.1016/j.jpeds.2007.03.002 View ArticleGoogle Scholar
  14. Lenarduzzi S, Morgutti M, Crovella S, Coiana A, Rosatelli MC (2014) Short communication: novel truncating mutations in the CFTR gene causing a severe form of cystic fibrosis in Italian patients. Genet Mol Res 13(4):9636–9641. doi:10.4238/2014.November.14.8 View ArticleGoogle Scholar
  15. Loumi O, Ferec C, Mercier B, Creff J, Fercot B, Denine R, Grangaud JP (2008) CFTR mutations in the Algerian population. J Cyst Fibros 7:54–59. doi:10.1016/j.jcf.2007.04.004 View ArticleGoogle Scholar
  16. Lubamba B, Dhooghe B, Noel S, Lea T (2012) Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy. Clin Biochem 45:1132–1144. doi:10.1016/j.clinbiochem.2012.05.034 View ArticleGoogle Scholar
  17. Messaoud T, Bel Haj Fredj S, Bibi A, Elion J, Ferec C, Fattoum S (2005) Molecular epidemiology of cystic fibrosis in Tunisia. Ann Biol Clin (Paris) 63:627–630Google Scholar
  18. Monaghan KG, Highsmith WE, Amos J, Pratt VM, Roa B, Friez M et al (2004) Genotype–phenotype correlation and frequency of the 3199del6 cystic fibrosis mutation among I148T carriers: results from a collaborative study. Genet Med 6:421–425View ArticleGoogle Scholar
  19. Naguib ML, Schrijver I, Gardner P, Pique LM, Doss SS, Abu Zekry MA et al (2007) Cystic fibrosis detection in high-risk Egyptian children and CFTR mutation analysis. J Cyst Fibros 6:111–116View ArticleGoogle Scholar
  20. Nahida el-R, Mohammed H, Guy L (2011) Pseudo-Bartter’s syndrome revealing cystic fibrosis in an infant caused by 3849 + 1G > A and 4382delA compound heterozygosity. Acta Paediatr 100:234–235. doi:10.1111/j.1651-2227.2011.02294.x View ArticleGoogle Scholar
  21. NCCLS (2000) Sweat testing: sample collection and quantitative analysis; approved guideline, 2nd edn. NCCLS document C34-A2. NCCLS, Wayne. ISBN: 1-56238-407-4Google Scholar
  22. Pereira L, Raskin S, Freund AA, Ribas PD, Castro R, Pignatti PF et al (1999) Cystic fibrosis mutations R1162X and 2183AA ® G in two southern Brazilian states. Genet Mol Biol 22:291–294. doi:10.1590/S1415-47571999000300002 View ArticleGoogle Scholar
  23. Rolfini R, Cabrini G (1993) Nonsense mutation R1162X of the cystic fibrosis transmembrane conductance regulator gene does not reduce messenger RNA expression in nasal epithelial tissue. J Clin Invest 92:2683–2687View ArticleGoogle Scholar
  24. Salvatore D, Tomaiuolo R, Abate R, Vanacore B, Manieri S, Mirauda MP et al (2004) Cystic fibrosis presenting as metabolic alkalosis in a boy with the rare D569G mutation. J Cyst Fibros 3:135–136. doi:10.1016/j.jcf.2004.01.007 View ArticleGoogle Scholar
  25. Shoshani T, Augarten A, Gazit E, Bashan N, Yahav Y, Rivlin Y et al (1992) Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with severe disease presentation. Am J Hum Genet 50:222–228Google Scholar
  26. Siryani I, Jama M, Rumman N, Marzouqa H, Kannan M, Lyon E et al (2015) Distribution of cystic fibrosis transmembrane conductance regulator (CFTR) mutations in a cohort of patients residing in palestine. PLoS ONE. doi:10.1371/journal.pone.0133890 Google Scholar
  27. Skeggs LT, Hochstrasser HC (1964) Thiocyanate (colorimetric) method of chloride estimation. Clin Chem 10:918–936Google Scholar
  28. Van Hoorenbeeck K, Storm K, van den Ende J, Biervliet M, Desager KN (2007) N1303K and IVS8-5T, clinical presentation within a family with atypical cystic fibrosis. J Cyst Fibros 6:220–222. doi:10.1016/j.jcf.2006.10.002 View ArticleGoogle Scholar
  29. Varon R, Stuhrmann M, Macek M Jr, Kufardjieva A, Angelicheva D, Magdorf K et al (1995) Pancreatic insufficiency and pulmonary disease in German and Slavic cystic fibrosis patients with the R347P mutation. Hum Mutat 6:219–225View ArticleGoogle Scholar
  30. Voter KZ, Clement LR (2008) Diagnosis of cystic fibrosis. Clin Rev Allergy Immunol 35:100–106. doi:10.1007/s12016-008-8078-x View ArticleGoogle Scholar
  31. Walker LC, Venglarik CJ, Anbin G, Weatherly MR, McCarty NA, Lesnick B et al (1997) Relationship between airway ion transport and a mild pulmonary disease mutation in CFTR. Am J Respir Crit Care Med 155:1684–1689View ArticleGoogle Scholar

Copyright

© The Author(s). 2016